MA33984B1 - Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique - Google Patents
Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystiqueInfo
- Publication number
- MA33984B1 MA33984B1 MA35118A MA35118A MA33984B1 MA 33984 B1 MA33984 B1 MA 33984B1 MA 35118 A MA35118 A MA 35118A MA 35118 A MA35118 A MA 35118A MA 33984 B1 MA33984 B1 MA 33984B1
- Authority
- MA
- Morocco
- Prior art keywords
- sgc
- treatment
- combination
- cystic fibrosis
- activators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Chemical And Physical Treatments For Wood And The Like (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne une guanylate cyclase soluble (sgc) et les phosphodiestérases (pde) et la pharmacologie des stimulateurs de sgc, activateurs de sgc et inhibiteurs de pde. Plus particulièrement, l'invention concerne l'utilisation de stimulateurs de sgc et d'activateurs de sgc en combinaison avec des inhibiteurs de pde5 pour la préparation de médicaments pour le traitement de la fibrose kystique (cf).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10152727 | 2010-02-05 | ||
PCT/EP2011/051532 WO2011095534A1 (fr) | 2010-02-05 | 2011-02-03 | Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33984B1 true MA33984B1 (fr) | 2013-02-01 |
Family
ID=43759663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35118A MA33984B1 (fr) | 2010-02-05 | 2011-02-03 | Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique |
Country Status (32)
Country | Link |
---|---|
US (1) | US20130035340A1 (fr) |
EP (1) | EP2531187B1 (fr) |
JP (2) | JP6143461B2 (fr) |
KR (1) | KR101793304B1 (fr) |
CN (3) | CN102770133A (fr) |
AU (1) | AU2011212521B2 (fr) |
BR (1) | BR112012019666A2 (fr) |
CA (1) | CA2788969C (fr) |
CL (1) | CL2012002173A1 (fr) |
CR (1) | CR20120408A (fr) |
CY (1) | CY1116878T1 (fr) |
DK (1) | DK2531187T3 (fr) |
EA (1) | EA025177B1 (fr) |
ES (1) | ES2548394T3 (fr) |
HK (1) | HK1212892A1 (fr) |
HR (1) | HRP20151187T1 (fr) |
HU (1) | HUE028008T2 (fr) |
IL (1) | IL221012B (fr) |
MA (1) | MA33984B1 (fr) |
MX (1) | MX342944B (fr) |
MY (2) | MY159697A (fr) |
NZ (1) | NZ601612A (fr) |
PL (1) | PL2531187T3 (fr) |
PT (1) | PT2531187E (fr) |
RS (1) | RS54336B1 (fr) |
SG (1) | SG182819A1 (fr) |
SI (1) | SI2531187T1 (fr) |
SM (1) | SMT201500286B (fr) |
TN (1) | TN2012000397A1 (fr) |
UA (1) | UA112962C2 (fr) |
WO (1) | WO2011095534A1 (fr) |
ZA (1) | ZA201205532B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA025177B1 (ru) * | 2010-02-05 | 2016-11-30 | Адверио Фарма Гмбх | СТИМУЛЯТОР sGC ИЛИ АКТИВАТОР sGC, ПРИМЕНЯЕМЫЙ ДЛЯ ЛЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С ИНГИБИТОРОМ PDE5 |
ME02207B (me) | 2010-05-26 | 2016-02-20 | Adverio Pharma Gmbh | UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc) |
EP2585055A1 (fr) * | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Utilisation de stimulateurs et d'activateurs de la guanylate-cyclase soluble pour le traitement de la drépanocytose et la conservation de substituts sanguins |
EP2594270A3 (fr) * | 2011-11-18 | 2013-07-31 | BIP Patents | Utilisation de stimulateurs de la sGC ou d'activateurs de la sGC, seuls et en combinaison avec des inhibiteurs de PDE5 pour le traitement de la sclérose systémique (Ssc) |
DK2892891T3 (da) * | 2012-09-07 | 2019-10-14 | Boehringer Ingelheim Int | Alkoxypyrazoler som opløselige guanylatcyklaseaktivatorer |
EP3024455A1 (fr) * | 2013-07-25 | 2016-06-01 | Bayer Pharma Aktiengesellschaft | Stimulateurs de sgc ou activateurs de sgc et inhibiteurs de pde5 en combinaison avec un autre traitement pour la thérapie de la fibrose kystique |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
US20160311826A1 (en) | 2013-12-11 | 2016-10-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
DK3172202T3 (da) | 2014-07-22 | 2020-04-27 | Boehringer Ingelheim Int | Heterocykliske carboxylsyrer som aktivatorer af opløselig guanylatcyclase |
US20170298055A1 (en) | 2014-09-17 | 2017-10-19 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
US20170291889A1 (en) | 2014-09-17 | 2017-10-12 | Ironwood Pharmaceuticals, Inc. | Pyrazole derivatives as sgc stimulators |
EP3194386A2 (fr) | 2014-09-17 | 2017-07-26 | Ironwood Pharmaceuticals, Inc. | Stimulateurs de sgc |
KR20180095594A (ko) | 2015-12-18 | 2018-08-27 | 노파르티스 아게 | 인단 유도체 및 가용성 구아닐레이트 시클라제 활성화제로서의 그의 용도 |
EP3554506B1 (fr) | 2016-12-16 | 2021-04-28 | Cystic Fibrosis Foundation | Dérivés d'hétéroaryle bycyclique en tant que potentialisateurs du cftr |
CN110305125B (zh) * | 2019-06-06 | 2021-09-03 | 山东新华制药股份有限公司 | 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958926A (en) * | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
CZ302691B6 (cs) * | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE102005016345A1 (de) * | 2005-04-09 | 2006-10-12 | Bayer Healthcare Ag | Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
DE102005047946A1 (de) * | 2005-10-06 | 2007-05-03 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
US20080081816A1 (en) * | 2006-10-03 | 2008-04-03 | Kaohsiung Medical University | Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3 |
RU2009145935A (ru) * | 2007-05-12 | 2011-06-20 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений |
WO2009032249A1 (fr) * | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Activateurs de la guanylate cyclase soluble |
WO2009068652A1 (fr) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | Pyridines 2, 6-disubstituées et pyrimidines 2, 4-disubstituées en tant qu'activateurs de guanylate cyclase soluble |
PE20091258A1 (es) | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
CA2720343A1 (fr) | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Derive heterocyclique et son utilisation |
JP2011523662A (ja) * | 2008-06-04 | 2011-08-18 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
EA025177B1 (ru) * | 2010-02-05 | 2016-11-30 | Адверио Фарма Гмбх | СТИМУЛЯТОР sGC ИЛИ АКТИВАТОР sGC, ПРИМЕНЯЕМЫЙ ДЛЯ ЛЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С ИНГИБИТОРОМ PDE5 |
-
2011
- 2011-02-03 EA EA201290702A patent/EA025177B1/ru not_active IP Right Cessation
- 2011-02-03 CN CN2011800083494A patent/CN102770133A/zh active Pending
- 2011-02-03 WO PCT/EP2011/051532 patent/WO2011095534A1/fr active Application Filing
- 2011-02-03 US US13/577,135 patent/US20130035340A1/en not_active Abandoned
- 2011-02-03 JP JP2012551615A patent/JP6143461B2/ja not_active Expired - Fee Related
- 2011-02-03 SI SI201130648T patent/SI2531187T1/sl unknown
- 2011-02-03 DK DK11701683.2T patent/DK2531187T3/en active
- 2011-02-03 PT PT117016832T patent/PT2531187E/pt unknown
- 2011-02-03 CA CA2788969A patent/CA2788969C/fr not_active Expired - Fee Related
- 2011-02-03 CN CN201711274967.9A patent/CN107929271A/zh active Pending
- 2011-02-03 SG SG2012056743A patent/SG182819A1/en unknown
- 2011-02-03 ES ES11701683.2T patent/ES2548394T3/es active Active
- 2011-02-03 AU AU2011212521A patent/AU2011212521B2/en not_active Ceased
- 2011-02-03 KR KR1020127020467A patent/KR101793304B1/ko active IP Right Grant
- 2011-02-03 MA MA35118A patent/MA33984B1/fr unknown
- 2011-02-03 NZ NZ601612A patent/NZ601612A/en not_active IP Right Cessation
- 2011-02-03 HU HUE11701683A patent/HUE028008T2/en unknown
- 2011-02-03 PL PL11701683T patent/PL2531187T3/pl unknown
- 2011-02-03 MX MX2012009011A patent/MX342944B/es active IP Right Grant
- 2011-02-03 RS RS20150716A patent/RS54336B1/en unknown
- 2011-02-03 BR BR112012019666A patent/BR112012019666A2/pt not_active Application Discontinuation
- 2011-02-03 MY MYPI2012003529A patent/MY159697A/en unknown
- 2011-02-03 CN CN201510259173.XA patent/CN104800219A/zh active Pending
- 2011-02-03 EP EP11701683.2A patent/EP2531187B1/fr active Active
- 2011-02-04 MY MYPI2012003528A patent/MY160856A/en unknown
- 2011-03-02 UA UAA201210468A patent/UA112962C2/uk unknown
-
2012
- 2012-07-18 IL IL221012A patent/IL221012B/en not_active IP Right Cessation
- 2012-07-23 ZA ZA2012/05532A patent/ZA201205532B/en unknown
- 2012-08-03 CL CL2012002173A patent/CL2012002173A1/es unknown
- 2012-08-03 TN TNP2012000397A patent/TN2012000397A1/en unknown
- 2012-08-06 CR CR20120408A patent/CR20120408A/es unknown
-
2015
- 2015-10-30 CY CY20151100972T patent/CY1116878T1/el unknown
- 2015-11-05 HR HRP20151187TT patent/HRP20151187T1/hr unknown
- 2015-11-19 SM SM201500286T patent/SMT201500286B/it unknown
-
2016
- 2016-01-26 HK HK16100823.5A patent/HK1212892A1/zh unknown
- 2016-05-09 JP JP2016093876A patent/JP6270907B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33984B1 (fr) | Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la fibrose kystique | |
MA32967B1 (fr) | Stimulateurs sgc d'activateurs sgc en combinaison avec des inhibiteurs pde5 dans le traitement du dysfonctionnement érectile | |
MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
TNSN08283A1 (en) | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | |
MA39094B1 (fr) | Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
PT2222669E (pt) | Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p) | |
MA38347A1 (fr) | Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak) | |
MA41654B2 (fr) | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton | |
MA37975A1 (fr) | Inhibiteurs de synthase de glucosylcéramide | |
EA201491697A1 (ru) | Составы агонистов гуанилатциклазы с и способы применения | |
MA34249B1 (fr) | Utilisation de stimulateurs de la sgc, d'activateurs de la sgc, seuls et en association avec des inhibiteurs de la pde5 en vue du traitement de la sclérodermie systémique | |
EA201690872A3 (ru) | Противовирусная терапия | |
EA200800726A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
MX2009009597A (es) | Derivados de amino-piridina como agonistas del receptor s1p1/edg1. | |
EP4275752A3 (fr) | Traitement d'addiction et de troubles de contrôle des impulsions au moyen d'inhibiteurs de la pde7 | |
RU2009120992A (ru) | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции | |
PH12014502294A1 (en) | Triazolo compounds as pde10 inhibitors | |
WO2013176877A3 (fr) | Traitement de la dépendance et des troubles du contrôle des impulsions à l'aide d'inhibiteurs de pde7 | |
EA200900552A1 (ru) | Пирроло[1,2-а]имидазолдион, эффективный при лечении периферической нейротоксичности, индуцированной химиотерапевтическими агентами | |
EP1909837B8 (fr) | Compositions pour le traitement de mastocytose systemique | |
MA37291A2 (fr) | Dérivés macrocycliques pour le traitement de maladies prolifératives | |
MA38056B1 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
TW200942540A (en) | Novel salt | |
SI1827461T1 (sl) | Kladribinski režim za zdravljenje multiple skleroze |